GENEREX BIOTECHNOL (GNBT)

0.80
0.20 20.00
OTC
Prev Close 1.00
Open 0.97
Day Low/High 0.65 / 1.00
52 Wk Low/High 2.24 / 4.59
Volume 417.50K
Exchange OTC
Shares Outstanding 35.08B
Market Cap 35.07M
Div & Yield N.A. (N.A)

Latest News

Generex Biotechnology Expands Medical Device & Wound Care Portfolio With Acquisition Of Regentys Corporation

Generex Biotechnology Expands Medical Device & Wound Care Portfolio With Acquisition Of Regentys Corporation

Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the company has signed a Binding Letter of Intent to acquire 51% of Regentys Corporation, a regenerative medicine company focused on developing treatments for patients with...

Generex Biotechnology Adds World-Class Leadership To Executive Management Team

Generex Biotechnology Adds World-Class Leadership To Executive Management Team

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced today the appointment of Anthony J.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced today the signing of a Letter of Intent to acquire 51 percent of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Announces Commercial Launch of FDA Approved Excellagen®, Proprietary, Patented Wound Care Product Focused on the Treatment of Complicated Wounds including Diabetic Ulcers and 16 Other FDA Approved Indications

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

NSABP to Provide Clinical Trial and Site Management Services for Antigen Express and Research Partner Merck on AE37/Keytruda® Combination Trial

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

Generex Biotechnology Corporation (OTCMKTS:GNBT) has signed a clinical trial agreement (CTA) with the NSABP Foundation, Inc.

Generex Provides Stock Market Alert

Generex Provides Stock Market Alert

Generex Biotechnology Corporation ( www.generex.

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Biotechnology Corporation ( www.generex.

Generex Announces Appointment Of Executive Management Team

Generex Announces Appointment Of Executive Management Team

Generex Biotechnology Corporation ( www.generex.

Generex Revises Record & Payment Dates For 20:1 Stock Dividend

Generex Revises Record & Payment Dates For 20:1 Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Publishes Update To Pending 20:1 Stock Dividend

Generex Publishes Update To Pending 20:1 Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Addresses The Opioid Crisis; Provides Proven, Non-Opioid Pain Management Solutions

Generex Addresses The Opioid Crisis; Provides Proven, Non-Opioid Pain Management Solutions

Generex Biotechnology Corporation ( www.generex.

Generex Announces REVISED Record & Payment Dates For 20:1 Stock Dividend

Generex Announces REVISED Record & Payment Dates For 20:1 Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Finalizes Acquisition Of Remaining Veneto Operating Assets

Generex Biotechnology Finalizes Acquisition Of Remaining Veneto Operating Assets

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Announces Record & Payment Dates For 20:1 Stock Dividend

Generex Biotechnology Announces Record & Payment Dates For 20:1 Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Confirms & Clarifies 20:1 Common Stock Dividend

Generex Confirms & Clarifies 20:1 Common Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Announces Launch Of NuGenerex Distribution Solutions

Generex Announces Launch Of NuGenerex Distribution Solutions

Generex Biotechnology Corporation ( www.generex.

Generex Announces Stock Dividend

Generex Announces Stock Dividend

Generex Biotechnology Corporation ( www.generex.

Generex Announces Closing Of First Tranche Acquisition Of Operating Assets

Generex Announces Closing Of First Tranche Acquisition Of Operating Assets

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Provides Update On AE37 Immuno-Therapeutic Clinical Development Program

Generex Biotechnology Provides Update On AE37 Immuno-Therapeutic Clinical Development Program

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Corporation Shareholder Alert

Generex Biotechnology Corporation Shareholder Alert

Generex Biotechnology Corporation ( www.generex.

Generex Launches NuGenerex Medical Marketing

Generex Launches NuGenerex Medical Marketing

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology To Present Overview Of Immuno-Oncology Development Program At Summit In Boston, MA

Generex Biotechnology To Present Overview Of Immuno-Oncology Development Program At Summit In Boston, MA

Generex Biotechnology Corporation ( www.generex.